South Korea Warns Weak Won Could Push Inflation Higher in 2025 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Asian Fund Managers Turn More Optimistic on Growth but Curb Equity Return Expectations: BofA Survey 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Oil Prices Rebound as Trump Orders Blockade of Sanctioned Venezuelan Tankers 
Japan Exports to U.S. Rebound in November as Tariff Impact Eases, Boosting BOJ Rate Hike Expectations 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Asian Currencies Slip as Dollar Strengthens; Indian Rupee Rebounds on Intervention Hopes 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Trump Orders Blockade of Sanctioned Oil Tankers, Raising Venezuela Tensions and Oil Prices 
Singapore Growth Outlook Brightens for 2025 as Economists Flag AI and Geopolitical Risks 
Silver Prices Hit Record High as Safe-Haven Demand Surges Amid U.S. Economic Uncertainty 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Chinese Robotaxi Stocks Rally as Tesla Boosts Autonomous Driving Optimism 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
